Agenus Inc. (AGEN)
Automate Your Wheel Strategy on AGEN
With Tiblio's Option Bot, you can configure your own wheel strategy including AGEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AGEN
- Rev/Share 4.0674
- Book/Share -2.5373
- PB -1.6277
- Debt/Equity -0.8695
- CurrentRatio 0.1111
- ROIC 12.4527
- MktCap 113231384.0
- FreeCF/Share -5.9577
- PFCF -0.7767
- PE -0.5301
- Debt/Assets 0.2696
- DivYield 0
- ROE 1.0634
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US
Published: June 03, 2025 by: Business Wire
Sentiment: Neutral
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as “Zydus,” designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensilimab and balstilimab (BOT/BAL). The strategic collaboration includes an exchange of Agenus' state-of-t.
Read More
Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide
Published: May 23, 2025 by: Seeking Alpha
Sentiment: Positive
I remain cautiously optimistic about Agenus, driven by BOT/BAL's strong clinical data and cost-reduction efforts, but maintain a speculative 2/5 conviction rating. The BOT/BAL program shows promising efficacy in MSS colorectal cancer, potentially resetting the standard of care and offering a significant commercial opportunity. Agenus's restructuring, asset monetization, and cost cuts aim to extend the runway and avoid near-term dilution, but financial risks and execution remain key concerns.
Read More
Despite Fast-paced Momentum, Agenus (AGEN) Is Still a Bargain Stock
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agenus (AGEN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Read More
Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025
Published: May 15, 2025 by: Business Wire
Sentiment: Neutral
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab (BOT/BAL) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Barcelona, Spain. A poster presentation will feature updated findings from an expanded cohort of 12.
Read More
Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Agenus Inc. (NASDAQ:AGEN ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations Garo Armen - Chairman and CEO Steven O'Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Richard Goldberg - Chief Development Officer Christine Klaskin - VP Finance and Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Mayank Mamtani - B.
Read More
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
Agenus (AGEN) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $3.04 per share a year ago.
Read More
Agenus Reports Q1 2025 Financial Results and Key Business Updates
Published: May 12, 2025 by: Business Wire
Sentiment: Neutral
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today reported financial and operational results for the first quarter of 2025, and shared key clinical and strategic milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) program. “The growing strength of our BOT/BAL data across multiple hard-to-treat cancers reinforces our conviction in its transformative potential and fuels our unwavering com.
Read More
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer
Published: May 12, 2025 by: Business Wire
Sentiment: Neutral
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation today announced that Dr. Richard M. Goldberg, an internationally recognized expert in gastrointestinal (GI) cancer treatment and research, has joined the company as Chief Development Officer. In this role, Dr. Goldberg will lead efforts to advance the botensilimab/balstilimab (BOT/BAL) program for patients and guide the company's regulatory and development strategy as it prepares to re-engage g.
Read More
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report
Published: April 29, 2025 by: Business Wire
Sentiment: Neutral
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID:.
Read More
Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Agenus (AGEN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript
Published: March 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Agenus Inc. (NASDAQ:AGEN ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations, Corporate Development Garo Armen - Chairman and Chief Executive Officer Christine Klaskin - Vice President, Finance and Principal Financial and Accounting Officer Steven O'Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Mayank Mamtani - B.
Read More
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
Published: March 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Agenus (AGEN) came out with a quarterly loss of $2.04 per share versus the Zacks Consensus Estimate of a loss of $2.36. This compares to loss of $2.60 per share a year ago.
Read More
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
Published: February 25, 2025 by: Business Wire
Sentiment: Neutral
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced participation in a panel discussion at the B. Riley Securities Precision Oncology & Radiopharma Investor Conference that will take place on Friday, February 28th in New York. Panel Discussion Details: Speaker: Robin Taylor, Ph.D., Chief Commercial Officer Topic: “What It Takes to Move the Needle in Improving Responses in Colorectal Cancer”' Date: 02/28/2025 Time: 1:00-2:00 p.m. ET Loc.
Read More
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
Published: February 24, 2025 by: Business Wire
Sentiment: Neutral
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting in Los Angeles, California. The oral presentation highlights translational data from the ongoing Phase 2 study evaluating botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1) in combination with MiNK Therapeutics' agenT-797, an allogeneic invariant natural killer T (iNKT).
Read More
CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
Published: February 23, 2025 by: Business Wire
Sentiment: Neutral
LEXINGTON, Mass.--(BUSINESS WIRE)--Proffered Papers, Session 2, Session Date and Time of release dated February 12, 2025, should read: Monday, February 24th, 1:39-1:45 p.m. PST (instead of Tuesday, February 25th, 1:00-1:45 p.m. PST). The updated release reads: AGENUS' BOT/BAL SELECTED FOR TWO PRESENTATIONS AT UPCOMING AACR IO ANNUAL MEETING Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Associa.
Read More
Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
Published: February 12, 2025 by: Business Wire
Sentiment: Neutral
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. An oral presentation will highlight interim data from the ongoing Phase 2 study of botensilimab and balstilimab (BOT/BAL) in combination with MiNK Therapeutics' iNKT cell therapy, AgenT-797,.
Read More
About Agenus Inc. (AGEN)
- IPO Date 2000-02-08
- Website https://www.agenusbio.com
- Industry Biotechnology
- CEO Dr. Garo H. Armen Ph.D.
- Employees 316